Skip to content
Biodatica
Start free

LEO Pharma

Copenhagen NV

OncologyPhase II
Compare Sign in to watch

What changed

Study registered, no phase assigned: Transcriptomic Analysis and Optical Coherence Tomography Combined for Patients With Basal Cell Carcinoma

10mo agoTrial registeredSep 19, 2025Source filing (opens the source filing in a new tab)

Momentum

61no change

Momentum 61 out of 100, unchanged since the last recompute.

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

1,843 pre-ticker oncology companies at Phase II

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    Study registered

    Jan 6, 2025

    Basal Cell Carcinomas · COMPLETED · sponsor: Bispebjerg Hospital · Transcriptomic Analysis and Optical Coherence Tomography Combined for Patients With Basal Cell Carcinoma

    ClinicalTrials.gov · NCT06813833 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Mar 10, 2022

    Solid Organ Transplant Recipient, Skin Cancer, Skin Dysplasia, HPV Infection, Cervical Intraepithelial Neoplasia, Cervical Cancer, HPV-Related Malignancy · RECRUITING · sponsor: Merete Haedersdal · The Organ Transplant Recipient HPV and Skin Cancer Study

    ClinicalTrials.gov · NCT05284877 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Feb 1, 2015

    Anogenital Warts · COMPLETED · sponsor: LEO Pharma · Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

    ClinicalTrials.gov · NCT02377999 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources